Clinical trial
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small…
NCT00298896 · Sunesis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00298896 |
|---|---|
| Title | Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer |
| Official title | Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC) |
| Lead sponsor | Sunesis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell, Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | SNS-595 |
| Enrollment | 55 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Mar 3, 2006 |
| Last update posted | Jul 26, 2018 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: